SCHUCHERT JOSEPH S

Form 4 January 26, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Section 16.

Form 4 or

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(1)

(Print or Type Responses)

1. Name and Address of Reporting Person * KELSO INVESTMENT ASSOC V LP

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(First)

(Street)

(State)

(Middle)

(Zip)

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

(Check all applicable)

3. Date of Earliest Transaction (Month/Day/Year)

Director Officer (give title below)

10% Owner Other (specify

320 PARK AVENUE

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line) Form filed by One Reporting Person

Filed(Month/Day/Year)

01/24/2006

X Form filed by More than One Reporting

Person

Table I. Non Derivative Securities Acquired Disposed of an Reposicially Ou

NEW YORK, NY 10022

` *	, ,	Table 1 - Non-Derivative Securities Acquired, Disposed of, or beneficially Owned							
1.Title of Security	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if	3. Transactio	4. Securities A		red (A)	5. Amount of Securities	6. Ownership	7. Nature of Indirect
(Instr. 3)	(any	Code	(Instr. 3, 4 an	` ′		Beneficially	Form:	Beneficial
		(Month/Day/Year)	(Instr. 8)				Owned Following	Direct (D) or Indirect	Ownership (Instr. 4)
					(A) or		Reported Transaction(s)	(I) (Instr. 4)	
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common									by Endo
Stock, par value \$.01 per share	01/24/2006		S	7,831,580	D	\$ 27.52	8,889,737	I	Pharma LLC (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

(3)

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. DrNumber of Derivative Securities Acquired (A) or Disposed		ate	7. Title Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans
				of (D)						(Instr
				(Instr. 3, 4, and 5)						
				, ,				Amount		
					Date Exercisable	Expiration Date	Title	or Number of		
			Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
KELSO INVESTMENT ASSOC V L P 320 PARK AVENUE NEW YORK, NY 10022		X					
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
Loverro Frank J C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					

Reporting Owners 2

WALL THOMAS R IV

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Connors James J II

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Signatures

/s/James J. Connors, II 01/26/2006

**Signature of Reporting Person Date

James J. Connors, II by Power of

Attorney 11/08/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/09/2005

Attorney 11/09/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of

Attorney 11/08/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Investment Associates V, L.P. (KIA $V^{\prime\prime}$) is the designated filer.

(2)

Signatures 3

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

KIA V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KIA V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KIA V, by virtue of his status as a general partner of the general partner of KIA V, and each individual shares investment and voting power along with the other general partners of KIA V, but disclaims beneficial ownership of such securities except to the extent of his pecuriary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.